A new luminescence assay for autoantibodies to mammalian cell-prepared insulinoma-associated protein 2

31Citations
Citations of this article
20Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

OBJECTIVE - Insulinoma-associated protein 2 (IA-2) is a major autoantigen in type 1 diabetes, and IA-2 autoantibodies are routinely detected by a liquid-phase radioimmunoprecipita-tion assay. The present experiments were initiated to develop a new assay that does not require the use of radioisotopes or autoantigens prepared in bacteria or by in vitro transcription/translation. RESEARCH DESIGN AND METHODS - IA-2 luciferase fusion protein was expressed in mammalian cells and assayed for autoantibodies by liquid-phase luciferase immunoprecipitation. RESULTS - Our study showed that there was no significant difference between the luciferase immunoprecipitation and the radioimmunoprecipitation assays in sensitivity and specificity, and comparison of the two assays revealed a high correlation coefficient (R 2 = 0.805). CONCLUSIONS - The luciferase system offers a robust, inexpensive, nonradioactive method for the detection of autoantibodies to mammalian cell-prepared IA-2 and could be of practical value at the clinical level. © 2008 by the American Diabetes Association.

Cite

CITATION STYLE

APA

Burbelo, P. D., Hlrai, H., Leahy, H., Lernmark, A., Ivarsson, S. A., Iadarola, M. J., & Notkins, A. L. (2008). A new luminescence assay for autoantibodies to mammalian cell-prepared insulinoma-associated protein 2. Diabetes Care, 31(9), 1824–1826. https://doi.org/10.2337/dc08-0286

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free